スピロノラクトン：男性型・女性型脱毛症（AGA）

合計6,273名の参加者を対象とした25件の研究（メタアナリシス4件、RCT 2件を含む）に基づく。25件中19件の研究で肯定的な効果が示されている。

𝕏 LinkedIn

<\/script>\n

`; }, get iframeSnippet() { const domain = 'haircited.com'; const params = 'ingredient\u003Dspironolactone\u0026condition\u003Dandrogenetic\u002Dalopecia'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style

Widget powered by . Free, no account required.

結論

Spironolactone is well-supported by research as an anti-androgen medication that may help reduce hair loss in androgenetic alopecia, particularly in women, though it requires medical supervision.

76% of studies show positive effects, backed by 4 meta-analyses
Works by blocking androgen hormones that contribute to hair miniaturization
Particularly studied in women with PCOS-related and female pattern hair loss
Requires prescription and medical monitoring due to hormonal effects

Key Study Findings

Review

Androgenetic Alopecia in Women: A Narrative Review of Pathophysiology, Clinical Evaluation, and Treatments.

Dose: None vs: None Outcome: None 効果: None None

対象集団: women with androgenetic alopecia (female pattern hair loss)

Review

Male and female pattern hair loss.

Dose: None vs: Placebo 効果: None None

RCT n=48 24 weeks Double-blind

Efficacy and safety of oral spironolactone for female pattern hair loss in premenopausal women: a …

Dose: Spironolactone 100 mg once daily vs: Placebo 効果: Terminal hair counts: 9.48 vs 5.32 hairs/cm2; hair diameter: 4.23 vs 2.96 μm; moderate-to-marked imp p=0.063 (terminal hair counts)

Randomized Controlled Trial n=125 4 weeks Double-blind

Effects of a cannabidiol/terpene formulation on sleep in individuals with insomnia: a double-blind, placebo-controlled, randomized, …

Dose: CBD 300 mg + 1 mg each of 8 terpenes vs: Placebo Outcome: Percentage of time in SWS + REM sleep 効果: 1.3% increase [0.1-2.5%]; up to 48 min/night in su 0.03

対象集団: Individuals with insomnia

Cohort Study n=203

An international multicenter, retrospective cohort study of 203 patients with pediatric androgenetic alopecia.

Dose: None vs: None Outcome: Clinical presentation and treatment outcomes in pediatric AGA 効果: None None

対象集団: Pediatric patients with androgenetic alopecia (multicenter)

Randomized Controlled Trial n=30

A Prospective and Comparative Study to Explore the Effects of Platelet-Rich Plasma in Hair Transplantation …

Dose: None vs: Drug therapy (minoxidil + finasteride/spironolactone) only Outcome: Follicle survival rate, growth rate, hair strength 効果: None None

対象集団: Patients with androgenetic alopecia

Key Statistics

研究数

6472

参加者数

↑

Positive

グレード

Referenced Papers

Androgenetic Alopecia in Women: A Narrative Review of Pathophysiology, Clinical Evaluation, and Treatments. Review

American journal of … 2026

Efficacy, safety and tolerability of drugs for alopecia: a comprehensive review. Review

Expert opinion on … 2025 11 件の引用

Nutritional deficiencies after sleeve gastrectomy and Roux-en-Y gastric bypass at 10 years: secondary analysis of the SLEEVEPASS randomized clinical trial. RCT

The British journal … 2025 10 件の引用

Epidemiological landscape of androgenetic alopecia in the US: An All of Us cross-sectional study. Other

PloS one 2025 8 件の引用

A Scoping Review of Exosome Delivery Applications in Hair Loss. Review

Cureus 2025 7 件の引用

Effects of a cannabidiol/terpene formulation on sleep in individuals with insomnia: a double-blind, placebo-controlled, randomized, crossover study. RCT

Journal of clinical … 2025 6 件の引用

A Prospective and Comparative Study to Explore the Effects of Platelet-Rich Plasma in Hair Transplantation for Patients With Androgenetic Alopecia. RCT

Journal of cosmetic … 2025 5 件の引用

Efficacy and safety of oral spironolactone for female pattern hair loss in premenopausal women: a randomized, double-blind, placebo-controlled, parallel-group pilot … Other

International journal of … 2025 3 件の引用

An international multicenter, retrospective cohort study of 203 patients with pediatric androgenetic alopecia. Other

Journal of the … 2025 3 件の引用

Non-classical congenital adrenal hyperplasia: current insights into clinical implications, diagnosis and treatment. Review

Endocrine 2025 2 件の引用

Male and female pattern hair loss. Review

Australian prescriber 2025 2 件の引用

Estrogen hormone therapy stabilizes lateral hairline in transfeminine patients: Implications for facial feminization surgery. Other

Journal of plastic, … 2025 1 件の引用

Evaluating the Role of the Gabrin Sign in Predicting COVID-19 Severity Among Patients with Androgenic Alopecia. Other

International journal of … 2025

The Hormonal Background of Hair Loss in Non-Scarring Alopecias. Review

Biomedicines 2024 17 件の引用

The efficacy of the combination of topical minoxidil and oral spironolactone compared with the combination of topical minoxidil and oral … RCT

Journal of cosmetic … 2024 14 件の引用

Management of androgenic alopecia: a systematic review of the literature. Systematic Review

Journal of cosmetic … 2024 11 件の引用

Safety of Antiandrogens for the Treatment of Female Androgenetic Alopecia with Respect to Gynecologic Malignancies. Review

Journal of clinical … 2024 11 件の引用

Cannabidiol (CBD) Inhibits Foam Cell Formation via Regulating Cholesterol Homeostasis and Lipid Metabolism. Other

Molecular nutrition & … 2024 5 件の引用

Comparative analysis of low-dose oral minoxidil with spironolactone versus finasteride or dutasteride in female androgenetic alopecia management. Other

Archives of dermatological … 2024 4 件の引用

Improving efficacy and maintaining safety in the treatment of alopecia with low-dose oral minoxidil and spironolactone combination therapy: A retrospective … Other

JAAD international 2024 1 件の引用

Potential of dietary hemp and cannabinoids to modulate immune response to enhance health and performance in animals: opportunities and challenges. Review

Frontiers in immunology 2023 99 件の引用

Androgenetic alopecia: An update. Review

JAAD international 2023 80 件の引用

Treatment of Androgenetic Alopecia: Current Guidance and Unmet Needs. Review

Clinical, cosmetic and … 2023 58 件の引用

The Efficacy and Safety of Oral and Topical Spironolactone in Androgenetic Alopecia Treatment: A Systematic Review. Review

Clinical, cosmetic and … 2023 25 件の引用

Androgenetic alopecia in transgender and gender diverse populations: A review of therapeutics. Review

Journal of the … 2023 24 件の引用

Medical and procedural treatment of androgenetic alopecia - Where are we? Review

Journal of the … 2023 20 件の引用

The Efficacy and Safety of Oral Spironolactone in the Treatment of Female Pattern Hair Loss: A Systematic Review and Meta-Analysis. Review

Cureus 2023 13 件の引用

Efficacy and safety profile of oral spironolactone use for androgenic alopecia: A systematic review. Systematic Review

Journal of the … 2022 24 件の引用

Efficacy and Safety of 5% Minoxidil Alone, Minoxidil Plus Oral Spironolactone, and Minoxidil Plus Microneedling on Female Pattern Hair Loss: … Case Report

Frontiers in medicine 2022 14 件の引用

Primary care provider attitudes, experiences and practices about cannabidiol (CBD) and barriers to patient-provider communication about CBD use: A qualitative … Other

PEC innovation 2022 11 件の引用

Observation on the Efficacy of a Combined Treatment for Moderate and Severe Androgenetic Alopecia Incorporating Electric Microneedles. Other

Clinical, cosmetic and … 2022 3 件の引用

The Role of Cannabidiol (CBD) in Chronic Pain Management: An Assessment of Current Evidence. Review

Current pain and … 2020 85 件の引用

Spironolactone use does not increase the risk of female breast cancer recurrence: A retrospective analysis. Other

Journal of the … 2020 19 件の引用

Herbal Medicines For Treatment of Androgenic Alopecia. Review

Alternative therapies in … 2020 11 件の引用

Female Pattern Hair Loss and Androgen Excess: A Report From the Multidisciplinary Androgen Excess and PCOS Committee. Meta-Analysis

The Journal of … 2019 101 件の引用

Androgens in women: Androgen-mediated skin disease and patient evaluation. Review

Journal of the … 2019 95 件の引用

Androgens in women: Hormone-modulating therapies for skin disease. Review

Journal of the … 2019 55 件の引用

Methods of treatment patients with androgenetic alopecia based on reference of Department of Dermatology in Cracow. Other

Polski merkuriusz lekarski … 2019 4 件の引用

Female pattern hair loss: A clinical, pathophysiologic, and therapeutic review. Review

International journal of … 2018 129 件の引用

Prescribing Habits for Androgenic Alopecia Among Dermatologists in Spain in 2017: A Cross-Sectional Study. Other

Actas dermo-sifiliograficas 2018 9 件の引用

Androgenic alopecia: an entity to consider in adolescence. Case Report

BMJ case reports 2017 6 件の引用

Interventions for female pattern hair loss. Meta-Analysis

The Cochrane database … 2016 18 件の引用

Selected Disorders of Skin Appendages--Acne, Alopecia, Hyperhidrosis. Review

The Medical clinics … 2015 66 件の引用

Evidence-based approach to cutaneous hyperandrogenism in women. Review

Journal of the … 2015 50 件の引用

Female pattern hair loss. Review

Current problems in … 2015 8 件の引用

Follicular delivery of spironolactone via nanostructured lipid carriers for management of alopecia. Other

International journal of … 2014 113 件の引用

Female pattern alopecia: current perspectives. Review

International journal of … 2013

Hair loss in women: medical and cosmetic approaches to increase scalp hair fullness. Review

The British journal … 2011 96 件の引用

Innovative use of spironolactone as an antiandrogen in the treatment of female pattern hair loss. Other

Dermatologic clinics 2010 80 件の引用

Hormonal therapy for acne: why not as first line therapy? facts and controversies. Review

Clinics in dermatology 2010

Hair loss in women. Review

Seminars in cutaneous … 2009 4 件の引用

A review of hormonal therapy for female pattern (androgenic) alopecia. Review

Dermatology online journal 2008

Treatment of female pattern hair loss with a combination of spironolactone and minoxidil. Case Report

The Australasian journal … 2007 32 件の引用

Association of androgenetic alopecia and hypertension. Other

European journal of … 2007

[Androgenetic alopecia]. Review

Revue medicale de … 2004

Practical recommendations for the use of ACE inhibitors, beta-blockers and spironolactone in heart failure: putting guidelines into practice. Other

European journal of … 2001 67 件の引用

Current aspects of antiandrogen therapy in women. Review

Current pharmaceutical design 1999

Management of androgenetic alopecia. Review

Journal of the … 1999

Hair regrowth. Therapeutic agents. Review

Dermatologic clinics 1998 121 件の引用

Beneficial effect of spironolactone on androgenic alopecia. Other

Clinical endocrinology 1997

Treatment of androgenic disorders with dexamethasone: dose-response relationship for suppression of dehydroepiandrosterone sulfate. Other

Journal of the … 1990

Oral spironolactone therapy for female patients with acne, hirsutism or androgenic alopecia. Other

The British journal … 1985

Dosage & Usage

mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units

一般的な使用量

hairloss:: 100-200 mg/day (prescription)

上限量： 200 mg/day (hair loss indication)

研究で検討された用量

用量	期間	効果	N
None	--	Neutral	--
None	--	Positive	--
Spironolactone 100 mg once daily	24 weeks	Positive	48
CBD 300 mg + 1 mg each of 8 terpenes	4 weeks	Positive	125
None	--	Positive	203
None	--	Positive	30
various across included studies (2015-2024)	--	Positive	--
None	--	Mixed	--

推奨摂取タイミング： Once or twice daily with food; prescription required

Safety & Side Effects

報告されている副作用

⚠ Menstrual irregularities
⚠ Breast tenderness
⚠ Hyperkalemia (elevated potassium levels)
⚠ Dizziness and orthostatic hypotension
⚠ Frequent urination

既知の相互作用

● ACE inhibitors and ARBs (increased hyperkalemia risk)
● Potassium supplements and potassium-sparing diuretics (dangerous hyperkalemia)
● NSAIDs (may reduce diuretic effectiveness and increase kidney risk)
● Digoxin (spironolactone may increase digoxin levels)

耐容上限摂取量： 200 mg/day (hair loss indication)

サプリメントの摂取を開始する前に、必ず医療専門家にご相談ください。

Frequently Asked Questions

Does スピロノラクトン help with 男性型・女性型脱毛症（AGA）?

Based on 45 studies with 6,472 participants, there is strong evidence from multiple clinical trials that スピロノラクトン may support 男性型・女性型脱毛症（AGA） management. Our evidence grade is A (Strong Evidence).

How much スピロノラクトン should I take for 男性型・女性型脱毛症（AGA）?

Studies have used various dosages. A commonly studied range is 100-200 mg/day (prescription). Always consult your healthcare provider before starting any supplement regimen.

Are there side effects of スピロノラクトン?

Reported side effects may include Menstrual irregularities, Breast tenderness, Hyperkalemia (elevated potassium levels), Dizziness and orthostatic hypotension. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.

How strong is the evidence for スピロノラクトン and 男性型・女性型脱毛症（AGA）?

We rate the evidence as Grade A (Strong Evidence). This rating is based on 45 peer-reviewed studies with 6,472 total participants. The overall direction of effect is positive.

Related Evidence

に関する他の成分：男性型・女性型脱毛症（AGA）

ミノキシジル A フィナステリド A PRP療法 A デュタステリド A オメガ3脂肪酸 A マイクロニードリング A

スピロノラクトン他の症状・状態について

女性型脱毛症 A

総合評価

合計6,273名の参加者を対象とした25件の研究（メタアナリシス4件、RCT 2件を含む）に基づく。25件中19件の研究で肯定的な効果が示されている。

Evidence Strength92%

High confidence

研究の内訳

RCT (4)Meta (2)Other (39)

代替成分との比較

この症状に対する他の成分との比較をご覧ください。

に関するすべての成分を見る：男性型・女性型脱毛症（AGA）

詳しく見る

FDAに関する免責事項: これらの記述は米国食品医薬品局（FDA）による評価を受けていません。本ウェブサイトの製品および情報は、疾病の診断、治療、治癒、または予防を目的としたものではありません。表示されているエビデンスグレードは、公開された査読済み研究の分析に基づいており、医療上の助言を構成するものではありません。サプリメントの摂取を開始する前に、必ず医療専門家にご相談ください。

スピロノラクトン ： 男性型・女性型脱毛症（AGA）